- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.07. | HCW Biologics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.07. | HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering | 524 | GlobeNewswire (Europe) | MIRAMAR, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion... ► Artikel lesen | |
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 30.06. | HCW Biologics regains Nasdaq compliance, plans stock split | 1 | Investing.com | ||
| 30.06. | HCW Biologics regains Nasdaq compliance | 1 | Seeking Alpha | ||
| 30.06. | HCW Biologics Inc.: HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter | 161 | GlobeNewswire (Europe) | MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (Nasdaq: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative... ► Artikel lesen | |
| 26.06. | HCW Biologics Commences 1-for-6 Reverse Stock Split | 1 | RTTNews | ||
| 26.06. | HCW Biologics executes 1-for-6 reverse stock split for Nasdaq | 2 | Investing.com | ||
| 26.06. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.06. | HCW Biologics Inc.: HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 | 343 | GlobeNewswire (Europe) | Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements... ► Artikel lesen | |
| 18.06. | HCW Biologics Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 16.06. | Microcap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair Loss | 1 | Benzinga.com | ||
| 16.06. | HCW Biologics Inc.: HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata | 254 | GlobeNewswire (Europe) | Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells Readout for dose-escalating clinical study for first two dose cohorts All participants... ► Artikel lesen | |
| 15.06. | HCW Biologics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.06. | HCW Biologics Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 01.06. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | HCW Biologics takes back rights to commercial-ready reagents | 2 | Seeking Alpha | ||
| 27.05. | HCW Biologics regains ex vivo rights to CAR-T therapy reagents | 1 | Investing.com | ||
| 27.05. | HCW Biologics Inc.: HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen | 1 | GlobeNewswire (USA) | ||
| 22.05. | HCW Biologics raises $4 million in private placement | 1 | Investing.com | ||
| 21.05. | HCW Biologics Inc. - 8-K, Current Report | - | SEC Filings |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 0,580 | +1,05 % | Inovio Pharmaceuticals, Inc.: INOVIO Announces Pricing of $20.0 Million Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen | |
| INFLARX | 1,585 | -0,69 % | InflaRx N.V.: InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones | Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as plannedInitiated feasibility assessment for broadened strategy for... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,300 | -0,39 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| IBIO | 1,264 | +3,27 % | iBio, Inc.: iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer | SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 74,84 | -1,29 % | Arrowhead plans sNDA by end of 2026 as SHASTA shows 79%-81% triglyceride reductions and 78% fewer pancreatitis events | ||
| IMMUNITYBIO | 6,550 | -0,76 % | IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake | ||
| IMMATICS | 8,280 | +2,92 % | Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 | Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MANNKIND | 3,540 | 0,00 % | H.C. Wainwright reiterates Buy rating on MannKind stock at $10 | ||
| IMMUNIC | 13,180 | +6,59 % | EQS-News: Immunic AG: Immunic to Participate in Investor Conferences in July | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor Conferences in July
09.07.2026 / 12:30 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 5,500 | +0,36 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates | U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas... ► Artikel lesen | |
| REVOLUTION MEDICINES | 176,85 | -0,42 % | Revolution Medicines: Steht der nächste Durchbruch bevor? Aktie auf Rekordhoch! | Die Biotech-Gesellschaft hat im Frühjahr mit einem Spätphasen-Erfolg zur Behandlung von zuvor therapiertem Bauchspeicheldrüsenkrebs für Furore gesorgt. Noch verfügt der Hoffnungsträger über keine offizielle... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,409 | -0,10 % | Moleculin Biotech, Inc.: Moleculin Announces Pricing of $9.3 Million Public Offering | HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced the pricing of a best-efforts public offering of an aggregate of... ► Artikel lesen | |
| GENPREX | 4,300 | +0,70 % | Genprex, Inc.: Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies | Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology
Validation Studies Aim to Optimize Clinical Trial Patient Selection... ► Artikel lesen | |
| MESOBLAST | 1,380 | +1,36 % | Mesoblasts führende Zelltherapie erzielt im ersten vollständigen Verkaufsjahr einen Umsatz von 115 Mio. US-Dollar | ||
| MACROGENICS | 3,360 | -4,00 % | MacroGenics, Inc.: MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026 | Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling... ► Artikel lesen |
HCW BIOLOGICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,52 % bei einem Aktienkurs von 3,530 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.